Global Parkinson’s Disease Therapeutics Market Is Expected to Reach Around USD 5.86 Billion By 2032

Zion Market Research has published a new report titled “Parkinson’s Disease Therapeutics Market By Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors, and Others), By Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032”. According to the report, the global parkinson’s disease therapeutics market size was valued at approximately USD 3.75 billion in 2023 and is predicted to reach around USD 5.86 billion by the end of 2032, expanding at a CAGR of around 5.1% from 2024 to 2032.

Parkinson’s disease (PD) is a nervous system disorder that increases in severity with time. The disease is characterized by bradykinesia, rigidity, tremor, and postural instability. Some of the most common symptoms of Parkinson’s disease include arm, hand, or leg tremors, problems associated with balancing and walking, stiff muscles, and slow physical movements. Other symptoms include constipation, trouble swallowing, dementia, fixed or blank expressions, and speech disabilities. The global Parkinson’s disease therapeutics market is likely to be driven by the increasing research and development activities for the development of novel Parkinson’s disease therapeutic drugs and rising Parkinson’s disease incidences. As per the Parkinson’s Foundation, around 8 to 10 million people worldwide are affected by Parkinson’s disease and every year approximately 70,000 Americans are diagnosed with it.

Browse the full “Parkinson’s Disease Therapeutics Market By Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors, and Others), By Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032” Report at https://www.zionmarketresearch.com/report/parkinsons-disease-therapeutics-market

Based on drug class, the market includes dopamine agonists, catechol-o-methyltransferase (COMT) inhibitors, anticholinergic drugs, levodopa combination, monoamine oxidase B (MAO-B) inhibitors, and others. The levodopa combination segment held a major share of the global market in 2023, as the levodopa combination therapy is among the highly effective treatments for controlling the motor symptoms at different stages of the Parkinson’s disease.

Based on the route of administration, the market includes transdermal, oral, subcutaneous, and intestinal infusion. The oral segment held a significant share of the global market in 2023. Additionally, the introduction of Duopa medicine in the U.S. contributed to a major share of the intestinal infusion segment in the global market.

The distribution channel of the Parkinson’s disease therapeutics market is fragmented into retail pharmacy, online sales, and hospital pharmacy. The retail pharmacy segment dominated the global market in 2023 and is projected to hold a significant market share in the future.

By region, Europe holds a major share of the global Parkinson’s disease therapeutics market followed by the North American region. Favorable medical reimbursement policies, rising funding and grants for research, high Parkinson’s disease prevalence, and growing awareness about the disease are contributing to the European Parkinson’s disease therapeutics market. In the North American market, alone there are more than 10 different drugs under phase III clinical pipeline studies for treating different symptoms of Parkinson’s disease in the U.S. alone. The Asia Pacific Parkinson’s disease therapeutics market is likely to show a moderate CAGR, owing to a large base of the elderly population suffering from Parkinson’s disease, particularly in China and Japan.

Some players in the global Parkinson’s disease therapeutics market are Teva Pharmaceutical, STADA Arzneimittel, Impax Laboratories, Novartis, F. Hoffmann-La Roche, Merck & Co., UCB Inc., GlaxoSmithKline, AbbVie, and Valeant Pharmaceuticals International.

This report segments the global Parkinson’s disease therapeutics market into:

Global Parkinson’s Disease Therapeutics Market: Drug Class Analysis

• Levodopa Combination
• Dopamine Agonists
• Monoamine Oxidase B (Mao-B) Inhibitors
• Anticholinergic Drugs
• Catechol-O-Methyltransferase (COMT) Inhibitors
• Others

Global Parkinson’s Disease Therapeutics Market: Route of Administration Analysis

• Oral
• Transdermal
• Subcutaneous
• Intestinal Infusion

Global Parkinson’s Disease Therapeutics Market: Distribution Channel Analysis

• Hospital Pharmacy
• Retail Pharmacy
• Online Sales

Global Parkinson’s Disease Therapeutics Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com